{"id":396383,"date":"2020-12-09T09:03:23","date_gmt":"2020-12-09T14:03:23","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=396383"},"modified":"2020-12-09T09:03:23","modified_gmt":"2020-12-09T14:03:23","slug":"amunix-presents-preclinical-data-on-amx-818-a-protease-activated-her2-targeted-t-cell-engager-prodrug-at-sabcs-2020","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/amunix-presents-preclinical-data-on-amx-818-a-protease-activated-her2-targeted-t-cell-engager-prodrug-at-sabcs-2020\/","title":{"rendered":"Amunix Presents Preclinical Data on AMX-818, a Protease-Activated HER2-Targeted T Cell Engager Prodrug, at SABCS 2020"},"content":{"rendered":"
\n

\n \u2013<\/em>
\n Data demonstrate potential of <\/em>
\n Amunix\u2019s<\/em>
\n XPAT<\/em>
\n (<\/em>
\n
\n X<\/em>
\n <\/strong>
\n TENylated<\/em>
\n
\n P<\/em>
\n <\/strong>
\n rotease<\/em>
\n –<\/em>
\n
\n A<\/em>
\n <\/strong>
\n ctivated <\/em>
\n
\n T<\/em>
\n <\/strong>
\n cell engager)<\/em>
\n platform to <\/em>
\n mitigate<\/em>
\n on-target, off-tumor toxicity that has hindered <\/em>
\n success <\/em>
\n of T cell engagers <\/em>
\n in <\/em>
\n treat<\/em>
\n ing<\/em>
\n solid tumors \u2013<\/em>
\n \n <\/p>\n

\n \u2013<\/em>
\n Lead program AMX-818, an <\/em>
\n XPAT<\/em>
\n prodrug<\/em>
\n targeting HER2, <\/em>
\n demonstrates potent efficacy with ~500-fold <\/em>
\n improved <\/em>
\n safety <\/em>
\n relative to unmasked<\/em>
\n , active<\/em>
\n form<\/em>
\n ,<\/em>
\n and no<\/em>
\n evidence of<\/em>
\n CRS <\/em>
\n \u2013<\/em>\n <\/p>\n

\n \u2013<\/em>
\n AMX-818 is effective<\/em>
\n in <\/em>
\n both HER2-high and HER-low <\/em>
\n tumor<\/em>
\n models<\/em>
\n , <\/em>
\n and continues progress toward clinic<\/em> \u2013<\/p>\n

SOUTH SAN FRANCISCO, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) — Amunix Pharmaceuticals, Inc. (\u201cAmunix\u201d), a biopharmaceutical company developing prodrugs of potent immune-activating biotherapeutics for the treatment of patients with solid tumors, today shared new data on AMX-818 (HER2-XPAT), the company\u2019s lead clinical candidate T cell engager which targets HER2. Data was presented at the 2020 San Antonio Breast Cancer Symposium.<\/p>\n

\u201cWe continue to be excited by progress of AMX-818 and its strong efficacy and safety data package,\u201d said Angie You, Ph.D., CEO of Amunix. \u201cNew in vivo<\/em> results demonstrating AMX-818 efficacy in a HER2-low tumor model support the potential to treat the significant population of patients with HER2-low and \u2013medium tumors who are not currently served by any HER2-targeting agents. In addition, because our universal masking technology is plug and play, we have been able to rapidly drive progress on two additional XPAT programs targeting PSMA and TROP2.\u201d<\/p>\n

Amunix presented a poster at SABCS, titled \u201cHER2-XPAT, A Novel Protease-Activatable Prodrug T Cell Engager (TCE), Engineered to Address On<\/em>-Target, Off<\/em>-Tumor Toxicity and Provide Large Predicted Safety Margins in Non-Human Primates\u201d. The poster shows that Amunix\u2019s XPAT technology can improve the toxicity profile of T cell engagers while maintaining their potency against solid tumors. In vitro<\/em>, protease-activated HER2-XPAT showed potent cytotoxic activity against tumor cell lines with EC50s in the single-digit pM range, while masking reduced target-directed T cell cytotoxicity and T cell activation by >10,000-fold. In established xenograft models, HER2-XPAT induced complete tumor regressions with efficacious doses within an order of magnitude of the unmasked (active) T cell engager. The ability to shrink large tumors was evident even after a single dose of HER2-XPAT, and the drug remained stable in circulation of tumor-bearing mice. Importantly, AMX-818 was also able to induce complete responses in xenograft tumors expressing low levels of HER2. This suggests the drug could have utility beyond HER2-high expressing cancer patients, addressing a large patient population that is not served by current HER2-targeting agents.<\/p>\n

Safety data from cynomolgus monkeys demonstrate that the masked XPAT prodrug has a markedly lower risk of CRS and enables a significant increase in maximum tolerated exposures relative to the unmasked, active form. In contrast to traditional unmasked T cell engagers, which have MTDs in the \u00b5g\/kg range, HER2-XPAT can be safely dosed up to 42 mg\/kg in cynos, representing a ~500-fold increase in tolerated exposures from masking. Combined with the potency of XPATs in xenograft models, these data suggest a favorable therapeutic index for AMX-818.<\/p>\n

\n
\n Poster Presentation Details<\/u>
\n <\/strong>
\n
\n Title:<\/strong> HER2-XPAT, A Novel Protease-Activatable Prodrug T Cell Engager (TCE), Engineered to Address On-Target, Off-Tumor Toxicity and Provide Large Predicted Safety Margins in Non-Human Primates
Abstract Number:<\/strong> PS17-11
Session:<\/strong> Virtual Poster Hall
Date:<\/strong> Available for Viewing Starting Dec 9<\/p>\n

Copies of the posters are available here<\/u><\/a>.<\/p>\n

\n About Amunix Pharmaceuticals<\/strong>\u00a0<\/p>\n

Amunix Pharmaceuticals, based in South San Francisco, CA, is focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers. The company is leveraging its proprietary T cell engager (XPAT) and cytokine (XPAC) platforms to advance a pipeline of novel prodrugs that are preferentially activated in the tumor microenvironment. Both platforms utilize Amunix\u2019s prodrug technology that has been clinically validated to extend drug half-life with limited immunogenicity. Amunix is advancing its lead development candidate, AMX-818, an XPAT T cell engager targeting HER2+ solid tumors, toward the clinic, and has several earlier programs underway, including programs targeting PSMA and TROP2. Amunix is also working on their first protease-activated masked cytokine program, IL12-XPAC, which is in discovery.<\/p>\n

For additional information about the company, please visit www.amunix.com<\/u><\/a>.<\/p>\n

\n Contacts<\/strong>\n <\/p>\n

\n Company Contact:<\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/p>\n

Zaneta Odrowaz\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0
Director, Corporate Development\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0
BD@amunix.com<\/u><\/a><\/p>\n

\u00a0<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

\u2013 Data demonstrate potential of Amunix\u2019s XPAT ( X TENylated P rotease – A ctivated T cell engager) platform to mitigate on-target, off-tumor toxicity that has hindered success of T cell engagers in treat ing solid tumors \u2013 \u2013 Lead program AMX-818, an XPAT prodrug targeting HER2, demonstrates potent efficacy with ~500-fold improved safety relative to unmasked , active form , and no evidence of CRS \u2013 \u2013 AMX-818 is effective in both HER2-high and HER-low tumor models , and continues progress toward clinic \u2013 SOUTH SAN FRANCISCO, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) — Amunix Pharmaceuticals, Inc. (\u201cAmunix\u201d), a biopharmaceutical company developing prodrugs of potent immune-activating biotherapeutics for the treatment of patients with solid tumors, today shared new data … <\/p>\n

Continue reading “Amunix Presents Preclinical Data on AMX-818, a Protease-Activated HER2-Targeted T Cell Engager Prodrug, at SABCS 2020”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-396383","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAmunix Presents Preclinical Data on AMX-818, a Protease-Activated HER2-Targeted T Cell Engager Prodrug, at SABCS 2020 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/amunix-presents-preclinical-data-on-amx-818-a-protease-activated-her2-targeted-t-cell-engager-prodrug-at-sabcs-2020\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Amunix Presents Preclinical Data on AMX-818, a Protease-Activated HER2-Targeted T Cell Engager Prodrug, at SABCS 2020 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"\u2013 Data demonstrate potential of Amunix\u2019s XPAT ( X TENylated P rotease – A ctivated T cell engager) platform to mitigate on-target, off-tumor toxicity that has hindered success of T cell engagers in treat ing solid tumors \u2013 \u2013 Lead program AMX-818, an XPAT prodrug targeting HER2, demonstrates potent efficacy with ~500-fold improved safety relative to unmasked , active form , and no evidence of CRS \u2013 \u2013 AMX-818 is effective in both HER2-high and HER-low tumor models , and continues progress toward clinic \u2013 SOUTH SAN FRANCISCO, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) — Amunix Pharmaceuticals, Inc. (\u201cAmunix\u201d), a biopharmaceutical company developing prodrugs of potent immune-activating biotherapeutics for the treatment of patients with solid tumors, today shared new data … Continue reading "Amunix Presents Preclinical Data on AMX-818, a Protease-Activated HER2-Targeted T Cell Engager Prodrug, at SABCS 2020"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/amunix-presents-preclinical-data-on-amx-818-a-protease-activated-her2-targeted-t-cell-engager-prodrug-at-sabcs-2020\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-09T14:03:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5OTA4OCMzODU3NjY4IzIwODgyODQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amunix-presents-preclinical-data-on-amx-818-a-protease-activated-her2-targeted-t-cell-engager-prodrug-at-sabcs-2020\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amunix-presents-preclinical-data-on-amx-818-a-protease-activated-her2-targeted-t-cell-engager-prodrug-at-sabcs-2020\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Amunix Presents Preclinical Data on AMX-818, a Protease-Activated HER2-Targeted T Cell Engager Prodrug, at SABCS 2020\",\"datePublished\":\"2020-12-09T14:03:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amunix-presents-preclinical-data-on-amx-818-a-protease-activated-her2-targeted-t-cell-engager-prodrug-at-sabcs-2020\\\/\"},\"wordCount\":717,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amunix-presents-preclinical-data-on-amx-818-a-protease-activated-her2-targeted-t-cell-engager-prodrug-at-sabcs-2020\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5OTA4OCMzODU3NjY4IzIwODgyODQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amunix-presents-preclinical-data-on-amx-818-a-protease-activated-her2-targeted-t-cell-engager-prodrug-at-sabcs-2020\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amunix-presents-preclinical-data-on-amx-818-a-protease-activated-her2-targeted-t-cell-engager-prodrug-at-sabcs-2020\\\/\",\"name\":\"Amunix Presents Preclinical Data on AMX-818, a Protease-Activated HER2-Targeted T Cell Engager Prodrug, at SABCS 2020 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amunix-presents-preclinical-data-on-amx-818-a-protease-activated-her2-targeted-t-cell-engager-prodrug-at-sabcs-2020\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amunix-presents-preclinical-data-on-amx-818-a-protease-activated-her2-targeted-t-cell-engager-prodrug-at-sabcs-2020\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5OTA4OCMzODU3NjY4IzIwODgyODQ=\",\"datePublished\":\"2020-12-09T14:03:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amunix-presents-preclinical-data-on-amx-818-a-protease-activated-her2-targeted-t-cell-engager-prodrug-at-sabcs-2020\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amunix-presents-preclinical-data-on-amx-818-a-protease-activated-her2-targeted-t-cell-engager-prodrug-at-sabcs-2020\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amunix-presents-preclinical-data-on-amx-818-a-protease-activated-her2-targeted-t-cell-engager-prodrug-at-sabcs-2020\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5OTA4OCMzODU3NjY4IzIwODgyODQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5OTA4OCMzODU3NjY4IzIwODgyODQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amunix-presents-preclinical-data-on-amx-818-a-protease-activated-her2-targeted-t-cell-engager-prodrug-at-sabcs-2020\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Amunix Presents Preclinical Data on AMX-818, a Protease-Activated HER2-Targeted T Cell Engager Prodrug, at SABCS 2020\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Amunix Presents Preclinical Data on AMX-818, a Protease-Activated HER2-Targeted T Cell Engager Prodrug, at SABCS 2020 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/amunix-presents-preclinical-data-on-amx-818-a-protease-activated-her2-targeted-t-cell-engager-prodrug-at-sabcs-2020\/","og_locale":"en_US","og_type":"article","og_title":"Amunix Presents Preclinical Data on AMX-818, a Protease-Activated HER2-Targeted T Cell Engager Prodrug, at SABCS 2020 - Market Newsdesk","og_description":"\u2013 Data demonstrate potential of Amunix\u2019s XPAT ( X TENylated P rotease – A ctivated T cell engager) platform to mitigate on-target, off-tumor toxicity that has hindered success of T cell engagers in treat ing solid tumors \u2013 \u2013 Lead program AMX-818, an XPAT prodrug targeting HER2, demonstrates potent efficacy with ~500-fold improved safety relative to unmasked , active form , and no evidence of CRS \u2013 \u2013 AMX-818 is effective in both HER2-high and HER-low tumor models , and continues progress toward clinic \u2013 SOUTH SAN FRANCISCO, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) — Amunix Pharmaceuticals, Inc. (\u201cAmunix\u201d), a biopharmaceutical company developing prodrugs of potent immune-activating biotherapeutics for the treatment of patients with solid tumors, today shared new data … Continue reading \"Amunix Presents Preclinical Data on AMX-818, a Protease-Activated HER2-Targeted T Cell Engager Prodrug, at SABCS 2020\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/amunix-presents-preclinical-data-on-amx-818-a-protease-activated-her2-targeted-t-cell-engager-prodrug-at-sabcs-2020\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-09T14:03:23+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5OTA4OCMzODU3NjY4IzIwODgyODQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amunix-presents-preclinical-data-on-amx-818-a-protease-activated-her2-targeted-t-cell-engager-prodrug-at-sabcs-2020\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amunix-presents-preclinical-data-on-amx-818-a-protease-activated-her2-targeted-t-cell-engager-prodrug-at-sabcs-2020\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Amunix Presents Preclinical Data on AMX-818, a Protease-Activated HER2-Targeted T Cell Engager Prodrug, at SABCS 2020","datePublished":"2020-12-09T14:03:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amunix-presents-preclinical-data-on-amx-818-a-protease-activated-her2-targeted-t-cell-engager-prodrug-at-sabcs-2020\/"},"wordCount":717,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amunix-presents-preclinical-data-on-amx-818-a-protease-activated-her2-targeted-t-cell-engager-prodrug-at-sabcs-2020\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5OTA4OCMzODU3NjY4IzIwODgyODQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amunix-presents-preclinical-data-on-amx-818-a-protease-activated-her2-targeted-t-cell-engager-prodrug-at-sabcs-2020\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/amunix-presents-preclinical-data-on-amx-818-a-protease-activated-her2-targeted-t-cell-engager-prodrug-at-sabcs-2020\/","name":"Amunix Presents Preclinical Data on AMX-818, a Protease-Activated HER2-Targeted T Cell Engager Prodrug, at SABCS 2020 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amunix-presents-preclinical-data-on-amx-818-a-protease-activated-her2-targeted-t-cell-engager-prodrug-at-sabcs-2020\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amunix-presents-preclinical-data-on-amx-818-a-protease-activated-her2-targeted-t-cell-engager-prodrug-at-sabcs-2020\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5OTA4OCMzODU3NjY4IzIwODgyODQ=","datePublished":"2020-12-09T14:03:23+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amunix-presents-preclinical-data-on-amx-818-a-protease-activated-her2-targeted-t-cell-engager-prodrug-at-sabcs-2020\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/amunix-presents-preclinical-data-on-amx-818-a-protease-activated-her2-targeted-t-cell-engager-prodrug-at-sabcs-2020\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amunix-presents-preclinical-data-on-amx-818-a-protease-activated-her2-targeted-t-cell-engager-prodrug-at-sabcs-2020\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5OTA4OCMzODU3NjY4IzIwODgyODQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5OTA4OCMzODU3NjY4IzIwODgyODQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amunix-presents-preclinical-data-on-amx-818-a-protease-activated-her2-targeted-t-cell-engager-prodrug-at-sabcs-2020\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Amunix Presents Preclinical Data on AMX-818, a Protease-Activated HER2-Targeted T Cell Engager Prodrug, at SABCS 2020"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/396383","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=396383"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/396383\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=396383"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=396383"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=396383"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}